SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Alnylam's headquarters building in Massachusetts
Drug Development
Alnylam Aces Phase III Cardio Trial, Eyes Label Expansion for RNAi Therapy
Alnylam’s Amvuttra reduced the risk of all-cause death or recurrent cardiovascular events by at least 28% in patients with transthyretin amyloidosis with cardiomyopathy, the company announced Monday.
June 24, 2024
 · 
3 min read
 · 
Tristan Manalac
Lilly Institute for Genetic Medicine building in Boston, Ma, USA, on November 11, 2023. Eli Lilly and Company is an American pharmaceutical company.
Drug Development
Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win
Data showed that Eli Lilly’s Zepbound could resolve obstructive sleep apnea in at least 43% of patients, solidifying the pharma’s case for label expansion.
June 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Girl stepping on a scale with a tape measure in front of her
Drug Development
Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass
Altimmune’s obesity candidate pemvidutide strongly preserved lean muscle mass, with fat accounting for more than 78% of weight lost by participants in a Phase II study.
June 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Sep 17, 2020 Fremont / CA / USA - Novo Nordisk headquarters in Silicon Valley; Novo Nordisk A/S is a Danish multinational pharmaceutical company
Drug Development
Novo’s Wegovy Shows Stronger Weight-Loss Effects in Women Than Men: Study
Novo Nordisk’s Wegovy elicited greater weight loss in women than in men with heart failure, according to data presented Sunday at the American Diabetes Association’s 2024 Scientific Sessions.
June 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Closeup view on the shaking hand of a person holding drinking glass suffering from Parkinson's disease
Drug Development
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint
Jazz Pharmaceuticals’ calcium channel modulator suvecaltamide in a mid-stage trial was unable to significantly lower tremor burden in patients with essential tremor, the company reported Thursday.
June 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Vertex Pharmaceuticals' headquarters in Boston, Massachusetts
Drug Development
Vertex Finally Reaches Pricing Deal With England’s NHS for Cystic Fibrosis Drugs
Vertex Pharmaceuticals’ three cystic fibrosis drugs—Kaftrio/Trikafta, Symkevi and Orkambi—will now be available through England’s National Health Service, following the signing of a long-term reimbursement agreement.
June 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Businessman rejecting money in white envelope offered by his partner in the dark, anti bribery concept - panoramic banner
Deals
Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company
Vanda Pharmaceuticals has rejected two unsolicited takeover offers, saying that they are “opportunistic attempts” to acquire the biotech at a heavily discounted price.
June 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Man prepares his GLP-1 injection
Drug Development
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative
Zealand Pharma’s petrelintide cut body weight by more than 8% on average, with a good overall safety and tolerability profile.
June 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in California
Policy
Lilly Takes More Legal Actions Over Compounded Tirzepatide, Warns About Counterfeits
Eli Lilly on Thursday said it is again suing spas and clinics over compounded and counterfeit forms of tirzepatide, the active ingredient in blockbusters Mounjaro and Zepbound, which the pharma says can cause harmful side effects.
June 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to the FTC's office in Washington, DC
Policy
FTC Supports PTO Push for Patent Settlement Scrutiny, Better Antitrust Oversight
The Federal Trade Commission is supporting the U.S. Patent and Trademark Office’s proposed new rules requiring parties to a patent dispute to disclose all settlement agreements, including pharmaceutical drug settlements.
June 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Dementia in senior people. Memory loss. Awareness of Alzheimer's, Parkinson's disease, stroke, seizure, or mental health. Neurology and Psychology care. Science and medicine concept
Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study
A new observational study from the University of Iowa points to the potential of alpha-blocker drugs, commonly used to treat enlarged prostates, as a preventive therapeutic option for dementia with Lewy bodies.
June 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: The National Institutes of Health's main building in Maryland
Drug Development
NIH Finds Non-Chemo Drug Combo Induces Lasting Remission in DLBCL Patients
National Institutes of Health researchers in a Phase Ib/II study found a five-drug combination elicits strong remission rates in diffuse large B-cell lymphoma patients without using chemotherapeutic agents.
June 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca's manufacturing facility in Sweden
Drug Development
AstraZeneca’s Truqap Flops in Phase III Triple-Negative Breast Cancer Trial
Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.
June 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Photo illustration of hundred dollar bill and graph
Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up
On the heels of last week’s announcements from Foresite Capital and J.P. Morgan Private Capital, Decheng is planning to raise $700 million for its fifth life sciences fund.
June 18, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's office in Dresden, Germany
Drug Development
GSK Reignites Blenrep Blockbuster Aspirations With Data from Phase III Studies
Promising data from the DREAMM-7 and DREAMM-8 trials have revitalized GSK’s blockbuster goals for its antibody-drug conjugate Blenrep, positioned as a second-line treatment for multiple myeloma.
June 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More